Who are Novantrone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colcrys, Ellence, Camptosar, Camptosar, Camptosar, Idamycin Pfs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mitoxantrone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Novantrone — Competitive Intelligence Brief

Novantrone (MITOXANTRONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase Inhibitor. Area: Oncology.

marketed Topoisomerase Inhibitor Serine/threonine-protein kinase pim-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Novantrone (MITOXANTRONE). Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Novantrone TARGET	MITOXANTRONE		marketed	Topoisomerase Inhibitor	Serine/threonine-protein kinase pim-1	1987-01-01
Colcrys	COLCHICINE	Scilex Pharms	marketed	Alkaloid [EPC]	Serine/threonine-protein kinase pim-1	1961-01-01
Ellence	EPIRUBICIN	Pfizer	marketed	Anthracycline Topoisomerase Inhibitor	Tyrosine-protein kinase Fyn	1999-01-01
Camptosar	irinotecan	Pfizer	marketed	Topoisomerase Inhibitor	topoisomerase I	1996-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	onivyde	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-06 — Camptosar · 8329213 · US
2027-01-06 — Camptosar · 8329213 · Compound · US
2028-08-29 — Camptosar · 8147867 · Compound · US
2028-08-29 — Camptosar · 8147867 · US
2033-06-12 — Camptosar · 9364473 · US
2033-06-12 — Camptosar · 9452162 · US
2033-06-12 — Camptosar · 9492442 · US
2033-06-12 — Camptosar · 9717724 · US
2033-06-12 — Camptosar · 9717724 · Method of Use · US
2033-06-12 — Camptosar · 9364473 · Method of Use · US
2033-06-12 — Camptosar · 12364691 · Method of Use · US
2033-06-12 — Camptosar · 11369597 · Method of Use · US
2033-06-12 — Camptosar · 9339497 · Method of Use · US
2033-06-12 — Camptosar · 9452162 · Method of Use · US
2033-06-12 — Camptosar · 9492442 · Method of Use · US
2033-06-12 — Camptosar · 10980795 · US
2033-06-12 — Camptosar · 11369597 · US
2033-06-12 — Camptosar · 9339497 · US
2033-06-12 — Camptosar · 10980795 · Method of Use · US
2036-08-19 — Camptosar · 11344552 · Method of Use · US
2036-10-15 — Camptosar · 10456360 · US
2036-10-15 — Camptosar · 10993914 · US
2036-10-15 — Camptosar · 12059497 · Formulation · US
2036-10-15 — Camptosar · 10456360 · Formulation · US
2036-10-15 — Camptosar · 10993914 · Formulation · US

Sponsor landscape (Topoisomerase Inhibitor class)

Pfizer · 3 drugs in this class
· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Novantrone — Competitive Intelligence Brief. https://druglandscape.com/ci/mitoxantrone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab